GlassScriptPhysician profile
Erica Elyse Knowles
NPI 1780295279
$2,840.99
in general payments reported to CMS, 2019-2025
24 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $432 · 2023: $525 · 2024: $448 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.89 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $396.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $367.68 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $282.61 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $167.55 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $164.51 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $114.03 | 2022-2025 | Verquvo, Capvaxive, Steglatro |
| Exact Sciences Corporation | $99.15 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $94.01 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $88.35 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.02 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $53.62 | 2021-2022 | |
| Mylan Specialty L.P. | $53.32 | 2021 | |
| Sumitomo Pharma America, INC. | $35.54 | 2025 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.28 | 2021-2023 | Tradjenta, Jardiance |
| Janssen Pharmaceuticals, INC | $29.63 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.94 | 2021 | |
| Genzyme Corporation | $27.22 | 2024 | |
| Dexcom, INC. | $26.74 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $25.27 | 2024 | Rexulti |
| Corcept Therapeutics | $24.59 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $22.90 | 2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.